The company calls the new health claim a milestone for the Japan market.
Photo © iStockphoto.com
Gelatin and collagen ingredients supplier Gelita (Eberbach, Germany) says its Verisol collagen peptides have earned a new health claim in Japan for promoting skin elasticity. The health claim is a Foods with Function Claim (FFC), allowing marketers to make a skin-elasticity-supporting claim on food labels in Japan.
“In Japan, collagen peptides are already well known as a ‘beauty from within’ ingredient,” explained Koji Tanabe, general manager, Gelita Japan, in a press release. “However, the granting of this health claim is a very important milestone for the market. Manufacturers can directly show consumers the proven health benefits of Verisol collagen peptides on their food labels. On top of that, the recommended daily dose of 2.5 g per day, and good technological properties, are also attracting new business developments with Verisol in Japan.”
The health claim allows food and beverage manufacturers to apply to use the claim on packaging that “This product contains Verisol collagen peptides. Verisol is reported to maintain skin elasticity and supports skin health.”
According to the press release, Verisol collagen peptides “stimulate the fibroblasts in the dermis, which substantially increases the synthesis of collagen, elastin, and proteoglycans—all of which are essential for skin elasticity. As a result, the epidermis is supported from beneath, and skin sagging is prevented.”
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.